This study evaluated the accuracy and reproducibility of a human portable blood glucose meter (PBGM) for canine and feline whole blood. Reference plasma glucose values (RPGV) were concurrently measured using glucose oxidation methods. Fifteen healthy dogs and 6 healthy cats were used for blood sampling. Blood glucose concentrations and hematocrits were adjusted using pooled blood samples for our targeted values. A positive correlation between the PBGM and RPGV was found for both dogs (y = 0.877, x = -24.38, r = 0.9982, n = 73) and cats (y = 1.048, x = -27.06, r = 0.9984, n = 69). Acceptable results were obtained in error grid analysis between PBGM and RPGV in both dogs and cats; 100% of these results were within zones A and B. Following ISO recommendations, a PBGM is considered accurate if 95% of the measurements are within ± 15 mg/dl of the RPGV when the glucose concentration is <100 mg/dl and within ±15% when it is ≥100 mg/dl; however, small numbers of samples were observed inside the acceptable limits for both dogs (11%, 8 of 73 dogs) and cats (39%, 27 of 69 cats). Blood samples with high hematocrits induced lower whole blood glucose values measured by the PBGM than RPGV under hypoglycemic, normoglycemic, and hyperglycemic conditions in both dogs and cats. Therefore, this device is not clinically useful in dogs and cats. New PBGMs which automatically compensate for the hematocrit should be developed in veterinary practice.
Introduction
Portable blood glucose meters (PBGMs) are widely used for the management of diabetes mellitus in dogs and cats. Various recently developed PBGMs are now commercially available from several companies. However, canine and feline blood glucose concentrations obtained from human PBGMs are comCorrespondence to: A. Mori, e-mail: amori@nvlu.ac.jp monly lower than those obtained from the hexokinase or glucose oxidase reaction, which is used to determine reference glucose values. Thus, the difference between blood glucose concentrations obtained from human PBGMs and reference glucose values should be evaluated before using PBGMs for dogs and cats. The GLUCOCARD X-mini plus (Arkray, Kyoto, Japan) provides rapid and highly accurate test results for human blood samples. The required sample volume is quite small (approximately 0.3 μl). The measuring time is 5 sec, and the measuring range is 10 to 600 mg/dl. However, this device has not been used for dogs and cats.
To evaluate the system accuracy and measurement reproducibility of newly developed PBGMs for veterinary practice, sufficient numbers of canine and feline hypoglycemic, normoglycemic, and hyperglycemic blood samples are needed. However, large numbers of diabetic dogs and cats are required for such experiments. Furthermore, side effects are inevitable when taking blood samples from animals in a hypoglycemic condition. Based on the International Organization for Standardization (ISO) recommendations, if hypoglycemic or hyperglycemic blood samples from diabetic patients are unavailable, euglycemic whole blood (WB) samples should be incubated to allow for erythrocyte glycolysis or a glucose solution should be added (Brito-Casillas et al. 2014; ISO 15197 2003 , ISO 15197 2013 . Using the above-described methods, the device accuracy can be more easily and safely evaluated using healthy canine and feline blood samples. Additionally, higher hematocrit values interfere with glucose measurement when using PBGMs (Brito-Casillas et al. 2014 , Domori et al. 2014 ). Therefore, it is also necessary to evaluate whether changes in hematocrit values affect glucose values measured by the GLUCOCARD X-mini plus.
The objective of this study was to compare the system accuracy and measurement reproducibility in canine WB measured by a PBGM device with reference glucose values. Pooled blood samples were used to achieve this objective. This is an easy and useful method for adjusting glucose concentrations and hematocrit values without using diabetic or hypoglycemic dogs and cats (ISO 15197 2003 , ISO 15197 2013 .
Materials and Methods
In total, 15 healthy dogs (8 castrated male and 7 spayed female beagles, 2-11 years old, 8.0-14.0 kg) and 6 healthy cats (6 castrated male domestic shorthairs, 2-8 years old, 4.9-6.0 kg) were used for this study. All dogs and cats were kept and maintained at the Nippon Veterinary and Life Science University.
All dogs and cats were tested for concurrent diseases by physical examination, complete blood cell counts, and serum biochemistry tests. This study was approved by the Nippon Veterinary and Life Science University Animal Research Committee.
Preprandial blood (6 ml for dogs, 10 ml for cats) was withdrawn from the jugular vein of all 15 dogs and 6 cats and placed into heparinized plastic tubes. WB and plasma samples from 73 samples (from 15 dogs) and 69 samples (from 6 cats) were used to assess accuracy. The collected venous blood samples were dispensed into tubes of the determined numbers (73 samples for dogs, 69samples for cats). Some dispensed tubes were used for normoglycemic blood samples. A highly concentrated glucose solution was added to some dispensed tubes to prepare samples at each concentration and create hyperglycemic blood samples. The volume of glucose solution was ≤1%. To reduce the glucose concentration, residual tubes were stored in a 36 o C water bath for 1 to 8 hr to allow for erythrocyte glycolysis and thus prepare the various hypoglycemic blood samples.
Normoglycemic and adjusted blood samples were measured with a GLUCOCARD X-mini plus PBGM. This device was operated and calibrated according to the manufacturer's instructions. Residual WB samples were immediately centrifuged at 2000 × g (PMC-060 Capsulefuge; Tomy, Tokyo, Japan) for 10 min to obtain the plasma and red blood cell fractions. The Glucose concentrations of each plasma sample were measured by the glucose oxidation method using an ADAMS Glucose GA-1153 analyzer (Arkray) to obtain the reference glucose values. The hematocrit values were adjusted by reducing the plasma or adding plasma to the samples using pooled euglycemic samples. After adjusting the hematocrit values, the glucose concentrations were adjusted by adding glucose solutions or incubating in a 36 o C water bath as previously mentioned. Finally, the agitated WB samples were measured with the PBGM. The WB samples were then centrifuged to obtain plasma samples for measurement of the reference glucose values.
Intra-assay reproducibility of the WB glucose concentrations was estimated using 3 pooled blood samples (hypoglycemic, normoglycemic, and hyperglycemic) with 30 replicates. Comparison of the reference glucose values (n = 1) with those obtained by the PBGM (n = 30) under different hematocrit percentages was also evaluated using 3 pooled canine and feline blood samples (hypoglycemic, normoglycemic, and hyperglycemic). The hematocrit percentage was classified as low (<37%), normal (37%-54%), or high (>54%) in dogs and low (<30%), normal (30%-47%), or high (>47%) in cats. Hematocrit was evaluated using the conductimetry method with a SPOTCHEM SG SG-1220 (Arkray). All measurements were performed at room temperature (20 o C-25 o C). A drop of blood was placed on the parafilm, and 30 PBGM devices were then touched to the drop of blood to measure the blood glucose concentration. All procedures were completed within 1 min. In the statistical analysis, values are expressed as mean ± standard deviation (SD). Spearman's rank correlation coefficient was used to identify significant correlations between measurements, and Spearman's correlation coefficient (r) was obtained using GraphPad Prism 6 (GraphPad Software, Inc., San Diego, CA). PBGM data were evaluated using the clinical relevant error grid analysis (Clarke et al. 1987 , Cox et al. 1997 . The error grid compares values measured by reference glucose values (x-axis) versus the PBGM values (y-axis) in 5 zones associated with the following 5 risk levels: zone A, clinically accurate; zone B, altered clinical action but no or minimal effect on clinical outcome; zone C, altered clinical action with a likely effect on clinical outcome; zone D, altered clinical action with considerable medical risk; and zone E, altered clinical action with dangerous consequences (Johnson et al. 2009 ). Error grid analysis was conducted using Excel 2007 SP3 (Microsoft Corporation, Redmond, WA). Bland-Altman difference plots were constructed for comparison of the results of the PBGM versus the reference glucose values using GraphPad Prism 6.
Results
When the PBGM and reference glucose values were examined for dogs and cats, a positive correlation was observed in both dogs (y = 0.877, x = -24.38, r = 0.9982, n = 73) and cats (y = 1.048, x = -27.06, r = 0.9984, n = 69).
Because the efficacy of the GLUCOCARD X-mini plus has not been determined in dogs and cats, it was important to assess its reproducibility and imprecision. Analytical evaluation of the glucose concentrations under hypoglycemia, normoglycemia, and hyperglycemia with the PBGM device indicated acceptable analytical imprecision, with intra-assay coefficients of variation not exceeding the commonly accepted 5% limit (Tables 1 and 2) .
Error grid analyses of all canine and feline blood glucose measurements revealed distributions within zones A and B (Fig. 1A and B, respectively) . Twenty-eight of 73 canine samples (38.4%) and 53 of 69 feline samples (76.8%) were plotted in zone A. Forty-five of 73 canine samples (61.6%) and 15 of 69 feline samples (21.7%) were plotted in zone B.
Bland-Altman plot analysis revealed a mean difference of -48.5 ± 23.63 mg/dl (bias ± SD) in dogs ( Fig.  2A) and -18.78 ± 11.05 mg/dl (bias ± SD) in cats (Fig.  2B) According to the ISO 15197:2013 requirements for human use, a PBGM is considered accurate if 95% of the measurements are within ±15 mg/dl of the reference value when the glucose concentration is <100 mg/dl, and within ±15% when the glucose concentration is ≥100 mg/dl (Melihn and Wagner 2014). From the above criteria, the small samples in the present study were inside the calculated acceptable limits (8 of 73 dogs, 11%; 27 of 69 cats, 39%) between the PBGM and the reference glucose values.
Different hematocrit values were evaluated under hypoglycemic, normoglycemic, and hyperglycemic conditions in dogs and cats. The canine reference plasma glucose concentrations for hypoglycemia, normoglycemia, and hyperglycemia were 68.9, 115.8, and 375.8 mg/dl, respectively. However, blood samples with high hematocrits induced lower blood glucose values than those with low hematocrits using the PBGM under hypoglycemic, normoglycemic, and hyperglycemic conditions in dogs (Table 3 ). The feline reference plasma glucose concentrations for hypoglycemia, normoglycemia, and hyperglycemia were 64.4, 131.4, and 371.9 mg/dl, respectively. However, blood samples with high hematocrits induced lower blood glucose values than those with low hematocrits using the PBGM under hypoglycemic, normoglycemic, and hyperglycemic conditions in cats (Table 4) .
Discussion
PBGMs can allow for rapid blood glucose monitoring with a small volume of blood in diabetic dogs and cats. However, because the accuracy and reproduction of PBGMs depend on each device, newly developed human PBGMs should be evaluated for veterinary use in dogs and cats.
A high level of correlation between the PBGM and reference glucose values was observed in dogs and cats in the present study. Furthermore, the intra-assay coefficients of variation of the PBGM were <5% in both dogs and cats. Thus, the PBGM used in the current study showed high correlation, reliability, and reproducibility.
For clinical use of a PBGM, 99% of the values should be within zones A and B in the error grid analysis. In our study, 100% of the data points were within zones A and B of the error grid, indicating no effect or a minimal effect on clinical outcomes. However, a low percentage (38.4%) of canine samples were plotted in zone A. Meanwhile, a relatively high percentage (77.9%) of feline samples were plotted in zone A. However, these percentages are lower than the results of previous studies (dogs, 99.1%; cats, 92.5% plotted in zone A) (Domori et al. 2014) . Furthermore, according to the ISO 15197:2013 requirements, a small number of samples were inside the calculated acceptable limits (11% of dogs, 39% of cats) between the PBGM and the reference glucose values. With respect to the Bland-Altman plots, most of the canine data (96% of dogs, 96% of cats) were included in the 95% limits of agreement calculated from the PBGM and the reference glucose values. However, the ISO 15197:2013 requirements are considered strict clinical indices according to previous studies (Freckmann et al. 2012 , Brito-Casillas et al. 2014 , Khositseth et al. 2015 . Therefore, the GLUCOCARD X-mini plus is not applicable for veterinary practice, especially in dogs and cats.
The current study also evaluated whether hematocrit affects the PBGM accuracy. Specific PBGMs are affected by hematocrit values; anemic dogs and cats show higher WB glucose concentrations as measured by PBGMs than plasma reference glucose concentrations (Wess and Reusch 2000a ,b, Mori et al. 2011 , Brito-Casillas et al. 2014 . As a result, the hematocrit clearly interfered with the results obtained by the PBGM used in the current study. High hematocrits induced lower WB glucose concentrations as measured by the PBGM than did low hematocrits and plasma glucose concentrations measured with the reference glucose values. We were unable to determine why the hematocrit values affected the results. Factors such as differences in red blood cell size and thickness in dogs and cats and the lower glucose permeability in the red blood cells of these animals than of humans might have contributed; however, further studies are required (Magnani et al. 1978 , Higgins et al. 1982 , Rendell et al. 1985 , Barman et al. 1993 , Mori et al. 2011 .
This study has a number of limitations. First, we used pooled blood samples to evaluate the PBGM because of the small number of healthy dogs (n = 15) and healthy cats (n = 6). However, this limitation is also a strength because we were able to reduce the numbers of dogs and cats and avoid the side effects associated with hypoglycemic or hyperglycemic conditions in diabetic dogs and cats. Incubation of the samples or addition of glucose to the samples was thus performed to produce the various glucose concentrations. Second, to produce samples with various hematocrits, plasma and red blood cell RBC fractions were artificially adjusted. The samples used in the current study therefore might not be identical matches to blood samples in vivo. Third, PBGMs are typically used for capillary blood in the human clinical setting. The glucose level in capillary blood is approximately 20% to 25% higher than the glucose level in venous blood (Sacks 2006) . Therefore, it is also necessary to determine the accuracy when using capillary blood samples in veterinary practice.
In conclusion, the GLUCOCARD X-mini plus is not in agreement with the reference glucose values in dogs and cats. Furthermore, changes in the hematocrit obviously affect the WB glucose concentration as measured by the GLUCOCARD X-mini plus. Therefore, this device is not clinically useful in dogs and cats. It is also important to understand the possibility that the hematocrit will affect the measurement re-sults of the blood glucose concentration when using PBGMs other than the GLUCOCARD X-mini plus; these PGBMs do not have a hematocrit correction function. New PBGMs which automatically compensate for the hematocrit should be developed in veterinary practice in the future. Furthermore, our analysis methods using canine and feline pooled blood sampling for evaluation of a PBGM are useful for basic data acquisition before using actual clinically diabetic animals. This is because the required numbers of dogs and cats were relatively small and we could artificially adjust their blood glucose concentration and hematocrit values without any adverse effects on the dogs and cats. In the future, if newly developed PBGMs pass the methods used in the current study, their accuracy and reproducibility may then be evaluated in clinically diabetic animals.
